BioSpace News Archive

Syros Pharmaceuticals today announced the appointment of Conley Chee as the company’s first Chief Commercial Officer.

Twist Bioscience Corporation today announced the appointment of Dennis Cho as senior vice president, general counsel and chief ethics and compliance officer.

KSL Biomedical, Inc. announces expansion into Canada with the acquisition of Pulse Scientific, Inc.

Boehringer Ingelheim and Invetx are pleased to announce they have entered into a collaboration agreement to develop novel, species-specific monoclonal antibody (mAb) biotherapeutics targeting a wide range of diseases in the veterinary species, initially focused on dogs and cats.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted accelerated assessment to the Company’s lead product candidate, tabelecleucel (tab-cel®), for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).

Precision BioSciences, Inc. today announced an inducement grant for Michael Amoroso, newly appointed President and Chief Executive Officer of Precision BioSciences.

Thorne HealthTech (NASDAQ: THRN), a leader in developing innovative solutions for a personalized approach to health and wellbeing, today announced the closing of its initial public offering of 7,000,000 shares of common stock at a price of $10.00 per share, for total gross proceeds for the offering, before deducting the underwriting discounts and other offering expenses, of $70.0 million.

Innovent Biologics, Inc. and UNION therapeutics A/S today announced that they have entered into a strategic collaboration and license agreement for the development and commercialization of orismilast in China.

POXEL SA announced that the Poxel team will participate at several upcoming scientific conferences related to X-linked adrenoleukodystrophy, a severe orphan neurometabolic disease with no approved therapies.

Lipidor AB announced that the company’s Phase III clinical study of its drug candidate AKP02 for the treatment of psoriasis has been approved by the Indian Medical Products Agency and is ready to start.